1-[3-[[4-(2,7-Dimethylimidazo[1,2-a]pyridin-3-yl)-1,3-thiazol-2-yl]amino]phenyl]ethanone

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[3-[[4-(2,7-Dimethylimidazo[1,2-a]pyridin-3-yl)-1,3-thiazol-2-yl]amino]phenyl]ethanone
• 化学式: C₂₀H₁₈N₄OS
• 分子量: 362.4
• InChiKey: WKKDREJOJDHTDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  87.5
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] POLYCYCLIC GUANINE DERIVATIVE PHOSPHODIESTERASE V INHIBITORS<br/>[FR] INHIBITEURS DE LA PHOSPHODIESTERASE V DE DERIVES POLYCYCLIQUES DE GUANINE
  申请人：SCHERING CORP

  公开号：WO2003042216A1

  公开（公告）日：2003-05-22

  A compound having the formula (Ia) or (b), salt or solvate thereof, with the variables as defined herein, which can inhibit selectively phosphodiesterase V and can be useful for treating sexual dysfunction and other physiological disorders, symptoms and diseases

  具有化学式(Ia)或(b)的化合物，其盐或溶剂化物，其中变量的定义如此，可以选择性地抑制磷酸二酯酶V，并可用于治疗性功能障碍和其他生理障碍、症状和疾病。
• Thiazole compounds and methods of use
  申请人：Zhang Suoming

  公开号：US20070004711A1

  公开（公告）日：2007-01-04

  The present invention provides compounds, salts and hydrates of Formula I, wherein the variables Ar 1 , R 2 , R 3 , R 4 , r, q, and t are defined herein. Certain compounds of Formula I described herein possess potent antiviral activity. The invention also provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. Certain compounds described herein inhibit assembly of the HCV replication complex. The invention also provides pharmaceutical compositions containing one or more compounds of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with on or more other therapeutic agent.
• THIAZOLE COMPOUNDS AND METHODS OF USE
  申请人：Zhang Suoming

  公开号：US20120108576A1

  公开（公告）日：2012-05-03

  The present invention provides compounds, salts and hydrates of Formula I, wherein the variables Ar 1 , R 2 , R 3 , R 4 , r, q, and t are defined herein. Certain compounds of Formula I described herein possess potent antiviral activity. The invention also provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. Certain compounds described herein inhibit assembly of the HCV replication complex. The invention also provides pharmaceutical compositions containing one or more compounds of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with on or more other therapeutic agent.
• US8088806B2
  申请人：——

  公开号：US8088806B2

  公开（公告）日：2012-01-03